TrialInfection2022
Adjunctive interleukin-2 for the treatment of drug-susceptible tuberculosis: a randomized control trial in China.
Wenjuan Nie et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
2 papers cite it
this papercites it
TrialInfection2022
Wenjuan Nie et al.PubMed ↗Publisher ↗
No numbers read from the abstract.